#United States #Park City #MetaVia #MASH-TAG #DA-1726

MetaVia to Sponsor and Attend the MASH-TAG 2026 Conference

MetaVia Inc., a prominent name in the biotechnology sphere, is set to make waves at the upcoming 10th Annual MASH-TAG 2026 Conference, happening from January 8-10 at Chateaux Deer Valley in Park City, Utah. This event aims to address critical developments in cardiometabolic diseases, a field in which MetaVia is significantly invested.

About MetaVia Inc.

Founded with a mission to reshape the treatment landscape for cardiometabolic diseases, MetaVia has established itself as a clinical-stage biotechnology company focused on innovative solutions. Their current portfolio includes DA-1726 and vanoglipel, promising candidates for obesity and Metabolic Dysfunction-Associated Steatohepatitis (MASH).

DA-1726: A Potential Game-Changer

DA-1726 is an advanced oxyntomodulin analogue that operates as a dual agonist, targeting both glucagon-like peptide-1 receptors (GLP1R) and glucagon receptors (GCGR). This dual-action mechanism enables a reduction in food intake while enhancing energy expenditure, potentially leading to more considerable weight loss than traditional GLP1R agonists. In recent Phase 1 trials, DA-1726 showcased remarkable results, indicating its potential to set new standards in obesity management, thanks to its efficiency in weight reduction, glucose control, and waist circumference reduction.

Vanoglipel: Tackling MASH

On another front, MetaVia’s vanoglipel stands as a novel G-protein-coupled receptor 119 (GPR119) agonist with promising implications for liver health. Prior studies have demonstrated that vanoglipel positively influences liver inflammation, lipid metabolism, and glucose metabolism, and notably diminishes hepatic steatosis, inflammation, and fibrosis. A Phase 2a clinical investigation has given further credence to vanoglipel's ability to directly affect liver health while also stabilizing glucose levels.

Participation and Sponsorship at MASH-TAG 2026

By participating in and sponsoring the MASH-TAG 2026 Conference, MetaVia affirms its commitment to engaging with the broader healthcare community. Members from both their business development and clinical teams will be present, facilitating discussions, networking opportunities, and knowledge exchange regarding the latest advancements in the field of cardiometabolic health.

Conclusion

MetaVia’s involvement in MASH-TAG 2026 aims not only to showcase its groundbreaking research and therapeutic candidates but also to position the company as a leading innovator in the field of cardiometabolic disease treatment. For anyone interested in the future of these essential health issues, this conference will surely be a pivotal event.

For more insights and detailed information about MetaVia's innovative therapies, visit MetaVia's website.

Stay tuned for updates from the MASH-TAG 2026 Conference as MetaVia steps into the spotlight with its revolutionary ideas and solutions in addressing cardiometabolic diseases.